Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA. Katayama R, et al. Among authors: jessop na. Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25. Sci Transl Med. 2012. PMID: 22277784 Free PMC article.
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB. Kwak EL, et al. Among authors: jessop na. Cancer Discov. 2015 Dec;5(12):1271-81. doi: 10.1158/2159-8290.CD-15-0748. Epub 2015 Oct 2. Cancer Discov. 2015. PMID: 26432108 Free PMC article.
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB. Russo M, et al. Among authors: jessop na. Cancer Discov. 2016 Feb;6(2):147-153. doi: 10.1158/2159-8290.CD-15-1283. Epub 2015 Dec 7. Cancer Discov. 2016. PMID: 26644315 Free PMC article.
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI. Lin JJ, et al. Among authors: jessop na. J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373100 Free PMC article.
Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.
Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB. Hazar-Rethinam M, et al. Among authors: jessop na. Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5. Cancer Discov. 2018. PMID: 29431697 Free PMC article.
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.
Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV. Piotrowska Z, et al. Among authors: jessop na. JCO Precis Oncol. 2018;2018:PO.17.00263. doi: 10.1200/PO.17.00263. Epub 2018 Jul 16. JCO Precis Oncol. 2018. PMID: 30123863 Free PMC article.
Clinicopathologic Characteristics of BRG1-Deficient NSCLC.
Dagogo-Jack I, Schrock AB, Kem M, Jessop N, Lee J, Ali SM, Ross JS, Lennerz JK, Shaw AT, Mino-Kenudson M. Dagogo-Jack I, et al. J Thorac Oncol. 2020 May;15(5):766-776. doi: 10.1016/j.jtho.2020.01.002. Epub 2020 Jan 24. J Thorac Oncol. 2020. PMID: 31988001 Free article.
Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib.
Dagogo-Jack I, Manoogian A, Jessop N, Georgantas NZ, Fintelmann FJ, Farahani A, Digumarthy SR, Price MC, Folch EE, Keyes CM, Do A, Peterson JL, Mino-Kenudson M, Pitman M, Rivera M, Nardi V, Dias-Santagata D, Le LP, Iafrate AJ, Heist RS, Ritterhouse LR, Lennerz JK. Dagogo-Jack I, et al. JCO Oncol Pract. 2023 Sep;19(9):786-792. doi: 10.1200/OP.23.00031. Epub 2023 Jul 12. JCO Oncol Pract. 2023. PMID: 37437226 Free PMC article.
12 results